The Pharma Data

SEPTEMBER 7, 2021

Comer will oversee a team of physicians and nurses led by Jeanne Manubay, MD, the study’s medical director, who is monitoring the patients’ response to the vaccine, including their subsequent drug use and behaviors.

Clinical Trials 52

Clinical Trials Vaccine Trials Medical Schools 52

The Pharma Data

JULY 23, 2021

This approval is based on results from a multicenter, open-label, actively controlled clinical trial evaluating DALVANCE in pediatric patients from birth to less than 18 years of age with ABSSSI and 3 pharmacokinetic studies. There are no adequate and well-controlled studies with DALVANCE use in pregnant or nursing women.

FDA Approval 52

FDA Approval FDA Clinical Trials Trials 52

The Pharma Data

APRIL 8, 2021

Roche will present data on the increased use of home nursing capabilities in the Phase III GRADUATE studies of gantenerumab during the COVID-19 pandemic, which enabled home-bound trial participants to continue dosing to maintain medicine exposure. Alzheimer’s Disease (AD). P1: Aging and Dementia: Biomarkers.

Clinical Trials 52

Clinical Trials Trials Disease Therapies 52

The Pharma Data

OCTOBER 25, 2020

This trial is a multicenter, randomized, double-blind, placebo-controlled, ascending, dose-finding, adaptive Phase 2 study designed to evaluate the safety, pharmacokinetics and efficacy of BXCL501 in intensive care unit patients experiencing agitation associated with delirium, including COVID-19 patients.

Treatment 40

Treatment Trials FDA Hospitals 40

The Pharma Data

DECEMBER 3, 2020

Safety and Pharmacokinetics of Antisense Oligonucleotide STK-001 in Children and Adolescents with Dravet Syndrome: Single and Multiple Ascending Dose Design for the Open-Label Phase 1/2a MONARCH Study. The primary endpoints are safety, tolerability and pharmacokinetic (PK) profile of STK-001 in Dravet syndrome patients.

Clinical Trials 52

Clinical Trials Protein Expression Pharmacokinetics Trials 52

The Pharma Data

MARCH 25, 2021

Advise women not to breastfeed during IBRANCE treatment and for 3 weeks after the last dose because of the potential for serious adverse reactions in nursing infants. The pharmacokinetics of IBRANCE have not been studied in patients requiring hemodialysis. The most common adverse reactions (?10%) Source link:[link].

Therapies 52

Therapies Clinical Trials Trials Treatment 52

The Pharma Data

FEBRUARY 8, 2021

Advise women not to breastfeed during IBRANCE treatment and for 3 weeks after the last dose because of the potential for serious adverse reactions in nursing infants. The pharmacokinetics of IBRANCE have not been studied in patients requiring hemodialysis. The most common adverse reactions (?10%) About Pfizer Oncology.

Clinical Trials 52

Clinical Trials Treatment Therapies Production 52